|
Priyanka's Biotech Briefing
Distilled Bio uses AI to process and generate content for you. Verify important details using the linked sources.
Lilly will present new obesity-drug data, ivonescimab’s regulatory setback spotlights survival hurdles, and China adds CARsgen’s satri-cel to an innovative drug insurance list.
The top 10 stories from Fri Nov 13, 2026 07:04 AM to Mon Nov 16, 2026 07:05 AM
Generated November 16, 2026 at 7:05 AM
|
|
|
#1 Ivonescimab CRL Indicates OS Significance, Warning To Other PD-(L)1xVEGF Bispecifics Published 2026-11-16 Ivonescimab’s complete response letter highlights overall-survival significance as a potential regulatory hurdle for other PD-(L)1×VEGF bispecifics in advanced non-small cell lung cancer. Covered by: insights.citeline.com, biospace.com, fiercebiotech.com |
#2 Servier Presents Updated Four-Year Results from Phase 2 FIREFLY-1 Study of OJEMDA® (tovorafenib) in Pediatric Low-Grade Glioma (pLGG) at SNO 2026 Published 2026-11-14 Servier will present up to four years of follow-up data from its Phase 2 FIREFLY-1 study of tovorafenib in children with relapsed or refractory BRAF-altered low-grade glioma at SNO 2026. Covered by: prnewswire.com |
#3 CARsgen's CAR-T Product Satri-cel Included in China's Commercial Health Insurance Innovative Drug List Published 2026-11-14 CARsgen Therapeutics said China’s commercial health insurance innovative drug list now includes satri-cel, its autologous CAR T-cell therapy product CT041. Covered by: prnewswire.com |
#4 Novo submits etavopivat, an investigational once-daily therapy for adolescents and adults living with sickle cell disease, to the FDA and EMA for approval Published 2026-11-13 Novo submitted etavopivat for FDA and EMA approval, citing Phase 3 HIBISCUS trial efficacy and safety data in adolescents and adults with sickle cell disease. Covered by: prnewswire.com, prnewswire.com |
#5 Deaths, failed trials and other recent setbacks in the autoimmune space Published 2026-11-16 Novartis, Bristol Myers Squibb, argenx and other drugmakers have faced autoimmune-program setbacks, including discontinued assets, strategic pauses and safety concerns. Covered by: biospace.com |
#6 Global Sarcoma Therapy Now Available in Thailand Published 2026-11-15 Thailand’s FDA approved YONDELIS (trabectedin) for adults with advanced soft-tissue sarcoma who failed or cannot receive anthracycline and ifosfamide treatment. Covered by: prnewswire.com |
#7 Novo's Wegovy® was associated with a reduction in food noise according to real-world studies at ObesityWeek® 2026 Published 2026-11-14 Real-world SIGNAL study data found that adults taking injectable semaglutide had significantly lower food-noise scores within one month, with reductions continuing through six months. Covered by: prnewswire.com |
#8 Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale Published 2026-11-14 Lilly plans to present ObesityWeek 2026 data on Zepbound, Foundayo, EloraTZP and retatrutide, including Phase 2 results showing weight loss and A1C improvements with EloraTZP. Covered by: prnewswire.com |
#9 Rezolute Is Counting On One Plus One Equals Two Claims For Hyperinsulinism Candidate Published 2026-11-13 Rezolute reported positive Phase III results in tumor hyperinsulinism, potentially enabling simultaneous filings for that condition and congenital hyperinsulinism, and raised $100 million for commercial preparation. Covered by: insights.citeline.com |
#10 Cellectis could cut 70% of workforce in shift to in vivo therapies Published 2026-11-13 Cellectis may cut about 160 jobs, or 70% of its workforce, and has halted enrollment in two CAR T programs while prioritizing in vivo therapy trials. Covered by: biospace.com |